Marijuana Leader Canopy Growth (TSX:WEED) Fully Valued

Canaccord Genuity analyst Neil Maruoka thinks Canopy Growth Corp. (TSX:WEED) is the “dominant player” in the Canadian cannabis sector, but says the company’s stock is fully valued at current levels.

Aurora Cannabis Inc. Heading to Become #1

Aurora Cannabis Inc. (TSXV:ACB) is a high-flying Canadian medical marijuana producer that is slowly creeping up on Canopy Growth Corp. (TSX:WEED) and Aphria Inc. (TSXV:APH). The company has a $787 million market cap, but it could soon break the $1 billion mark later this year.

The High Risk of Investing in Medical Marijuana Inc.

Shareholders of Medical Marijuana Inc. ($MJNA , a company traded over-the-counter, have had a stellar year. So far, shares are up over 300% since February of last year. So why is this company such a high risk for new Investors?

GW Pharma Looks Better Than Ever to Investors

The world’s largest company involved with producing therapeutics derived from cannabis posted a fiscal first-quarter loss of $19.25 million.

GW Pharmaceuticals (NASDAQ:GWPH) said it lost $0.768 per American depository share (ADS) in its fiscal first quarter, well below analysts’ consensus estimate of $1.20. Each ADS represents 12 ordinary shares.

Aphria (TSXV:APH) Graduates to the TSX

Aphria (TSXV:APH, OTC:APHQF) is pleased to announce it has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its common shares on the TSX.

Crown Baus (OTC:CBCA) to Spend Upwards of $6m on Greenhouse Space

Crown Baus Capital Corp. (OTC:CBCA) is negotiating investment opportunity with Cannabis Science (CBIS) for Stake in California Property Development Projects and the Nevada Cannabinoid Drug Production Facilities in Douglas County, Nevada.

Phase 1 for each one acre build-out will cost approximately $300,000 to $500,000 USD with full production capacity maxing out at approximately 33,000 sq. ft.